A new quantitative method for estimating glomerular filtration rate and its clinical value.

BACKGROUND AND AIM: The estimation of the glomerular filtration rate (GFR) is essential for the renal function. However, all estimation methods for GFR have advantages and disadvantages. The aim of this study was to develop a new quantitative method for estimating GFR and evaluate its clinical value. METHODS: The new GFR was estimated by quantifying the accumulation of Tc-99m DTPA in the dual kidneys and bladder during a gamma camera renogram study in 116 patients with chronic kidney disease. GFR was determined by this new method (nGFR), Gates' gamma camera technique (gGFR), a two-plasma sampling method (tGFR) and creatinine-based clearance as estimated by Cockcroft-Gault (cGFR) and abbreviated MDRD (aGFR) formulae. The correlation analysis, Bland-Altman analysis and receiver-operating characteristic (ROC) plots were carried out among above methods. RESULTS: The nGFR value has significant correlation with tGRF (r = 0·827, P<0·01). The nGFR had the best overall performances with a lowest bias deviation (3·1 ml min(-1) /1·73 m(2) ), better precision (53·0 ml min(-1) /1·73 m(2) ), narrowest interquartile range (13·5 ml min(-1) /1·73 m(2) ) and best accuracy (68·1%) within 30% of the tGFR, compared with those of gGFR, cGFR and aGFR. The new method had the similar maximum accuracy with the Gates' method and creatinine clearance as estimated by Cockcroft-Gault and abbreviated modification of diet in renal disease (MDRD) method. The new method had better repeatability characteristic compared with the Gates' method. CONCLUSIONS: The new method for estimating GFR had the better performances compared with the Gates' method and creatinine clearance as estimated by Cockcroft-Gault and MDRD method.

Is bone mineral density measurement using dual-energy X-ray absorptiometry affected by gamma rays?

The objective of this study was to determine whether the gamma rays emitted from the radionuclide effect bone mineral density (BMD) measurement. Nine subjects (mean age: 56 ± 17.96 yr) scheduled for bone scanning underwent BMD measurement using dual-energy X-ray absorptiometry (DXA) (Hologic/Discovery A) before and 1, 2, and 4 h after injection of technetium-99m-methylene diphosphonate (99mTc-MDP). Ten subjects (mean age: 41 ± 15.47 yr) scheduled for therapy of differentiated thyroid carcinoma with iodine-131 underwent BMD measurement before and 2 h after therapeutic radionuclide administration. All patients were given whole body BMD measurement, including head, arm, ribs, lumbar spine, pelvis, and leg sites. Besides, patients who referred to radioiodine therapy were given total hip and femoral neck BMD measurement as well. No statistically significant changes in BMD values were detected after 99mTc-MDP and iodine-131 administration for all measurement sites (p > 0.05), and individual difference of BMD before and after radionuclide imaging or therapy was less than the least significant change in lumbar spine, total hip, and femoral neck. In conclusion, BMD measurements are not influenced by the gamma rays emitted from technetium-99m and iodine-131. DXA bone densitometry may be performed simultaneously with bone scanning and radioiodine therapy.